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ABSTRACT
Sepsis in humans has been an
enigma, with .100 clinical trials
failing to result in an effective drug
approved by the U.S. Food and Drug
Administration. It has long been
known that blood leukocytes from
patients with progressive sepsis
(clinically designated as severe
sepsis or septic shock) have defec-
tive innate immune and inflamma-
tory responses. In the report by
Patera et al. [1], blood leukocytes
(neutrophils, monocytes, CD8+
T cells, and NK cells) from septic
patients expressed increased
amounts of the "checkpoint" proteins
that consist of a family of surface
inhibitory molecules [programmed
cell death 1 (PD-1), programmed
cell death ligand 1 (PD-L1), CTLA-4,
B- and T-lymphocyte attenuator,
etc.] linked to PD. In the new report,
the emphasis is on PD-1 and PD-L1
on surfaces of blood leukocytes.
When these cells were examined in
vitro, they had defective functional
responses (phagocytosis and re-
lease of cytokines and IFN-g) and
reduced amounts of granzyme B
and CD107a expression. In vitro ad-
dition of blocking antibodies to PD-1
or PD-L1 (checkpoint molecules) to
blood leukocytes from septic hu-
mans restored innate immune re-
sponses. These data suggest that
PD-1 and PD-L1 suppress important
functional responses of blood neu-
trophils, monocytes, and various
lymphoid cells. The in vitro use of
blocking antibodies to these
checkpoint molecules appeared to
restore functional responses that
were suppressed during sepsis.
Modest restoration in vitro has re-
cently been reported in similar ear-
lier studies [2], and checkpoint
protein expression has been linked
to mortality in septic mice [3].
These findings have implications
for a new strategy to treat humans
with sepsis. J. Leukoc. Biol.
100: 1229–1231; 2017.
Human sepsis, occurring afterinfections with bacteria, viruses,fungi, or protozoa and condi-
tions of “sterile sepsis” (as after trauma
with hemorrhagic shock or chemical
injury of liver), results in a chain of events
in which the inflammatory and immune
systems are activated in an attempt to
control the early events of sepsis and to
restore the tissue to its preinjury state. If
all goes well in the setting of sepsis, the
inflammatory and immune responses will
recede, and tissues will be restored to
their normal state. Sepsis, by definition,
implies that something has gone wrong
with control mechanisms that regulate
these responses and that tissues are being
further injured by excessive inflammatory
and immune responses to intrinsic and
extrinsic factors [4]. Some of the reasons
for this harmful progression of events
may be age related (and perhaps also
gender associated), as well as a result of
the presence of comorbidities (e.g.,
hypertension, diabetes mellitus, obesity,
etc.) that interfere with recovery [5].
Another realization over the past few
years is that “recovery” from sepsis may be
subsequently associated with cognition
loss, reduced quality of life, and death
rates that when controlled for comorbid-
ity conditions, may result in a death rate
double that for a reference cohort [6].
There is no question that survival rates
from sepsis have been improved over the
past 2 decades. This relates to improved
support measures, such as aggressive fluid
management; intensive, early attempts to
identify the infectious agent; and
improved ventilation that reduces baro-
trauma. Obviously, there is a desperate
need for effective therapeutic strategies in
the early treatment of sepsis. As will be
suggested, the data in the report by
Patera et al. [1] may provide us with an
important alternative therapeutic inter-
vention for treatment of humans with
sepsis, using mAb that appear to be safe
for use in humans.
Checkpoint proteins (PD-1
and PD-L1) on surfaces
of leukocytes
It has been known for some time that 2
molecules (PD-1 and PD-L1), which occur
naturally on a variety of cells, negatively
regulate immune responses in the setting
of malignant tumors (melanomas or lung
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cancers that bear certain mutations) or
viral infections (HIV, EBV, hepatitis C
virus, etc.). These checkpoint molecules
are normally present in small amounts on
various cell types but are up-regulated in a
variety of circumstances. PD-1 is found
mainly on surfaces of T cells, whereas
PD-L1 is found on macrophages and
APCs [7, 8]. Sometimes both molecules
are present on the same cells. In the
setting of severe sepsis or septic shock,
these checkpoint proteins often demon-
strate increased expression and may be
responsible for the progressive immuno-
suppression of sepsis, as well as defective
mobilization of phagocytic cells (neutro-
phils, monocytes, macrophages) and
T cells, all of which seriously compromise
innate immune defenses against infec-
tious microbes (Fig. 1) [9]. When this
occurs, functional responses of neutro-
phils and monocytes are reduced
(phagocytosis, release of
proinflammatory mediators, etc.). In the
case of CD8+ T cells and NK cells,
increased expression of PD-1 and/or
PD-L1 has been associated with defective
IFN-g production and reduced levels of
granzyme B and CD107a, implying seri-
ous dysfunction in innate and adaptive
immune responses to infectious agents
[10]. Probably the most surprising obser-
vation in the Patera et al. [1] report was
the finding that when blood neutrophils,
monocytes, CD8+ T cells, or NK cells from
septic human donors were exposed in
vitro to neutralizing antibodies to PD-1
and/or PD-L1, the functional responses
of the leukocytes reappeared, which
represents a most surprising but welcome
outcome. When protein or peptide li-
gands bind to receptors on the surfaces of
phagocytes, the ligand–receptor complex
is usually internalized and transported to
the endoplasmic reticulum where the
ligand is hydrolyzed by acidic proteases,
allowing some of the receptor to be
recycled to the cell surface. Whether this
is happening with checkpoint–antibody




With the assumption that there are
plans to expand the preliminary data
substantially—suggesting that the block-
ing of antibodies to PD-1 and PD-L1 can
reverse defective innate immune re-
sponses of blood leukocytes from septic
humans—expanded and long-term studies
will be critically important. Based on anti-
bodies to PD-1 and PD-L1 in humans with
advanced melanomas or with lung cancer
[11], it seems that these antibodies are
reasonably safe for use in humans, al-
though this issue would have to be
pursued with carefully designed phase I
(safety) trials in septic patients. Further-
more, with the assumption that there will
not be serious roadblocks in designing
clinical trials and that there will be
uncontestable evidence that the anti-
bodies are safe and effective, this could
dramatically change the strategy for
treatment of humans with sepsis. In the
past, there has been consideration for use
of transfusion of various subtypes of
leukocytes to reverse the immunosup-
pression of sepsis (reviewed in refs.
[12, 13]). However, given the numerous
defects in phagocytes and in T cells in
septic humans, such a strategy would be
extremely labor intensive and would have
the problem of whether transfused
leukocytes could localize to critical areas
of infection, as well as how long they
would remain in the circulation. Fur-
thermore, there remain questions of
which type of infused cells would be most
effective. Such concerns could be moot if
early clinical trials indicate that antibodies
to PD-1 and PD-L1 can be demonstrated
to be clinically effective and safe in
humans with sepsis. If such a situation
were to occur, we would have a relatively
simple, effective, and safe therapeutic
approach to sepsis, for which evaluation
could include daily clinical assessments
and measurements by flow cytometry of
blood neutrophils, monocytes, and CD8+
T cells. If so, we might have a strategy that
Figure 1. PD-1 and PD-L1 impair innate immune responses of septic phagocytes. (Left) The
functional responses of phagocytes from mice or humans without sepsis. Activation of the cells with
LPS or a variety or other agonists results in enhanced phagocytosis and release of proinflammatory
mediators (cytokines and chemokines), as well as release of IFN-g. These products promote
inflammatory and innate and adoptive immune responses, resulting in protection against infectious
agents. (Middle) Blood phagocytes obtained from septic humans or mice. In this situation, sepsis
has led to up-regulation of PD-1 and PD-L1 on cell surfaces, resulting in suppressed innate
immune and inflammatory responses, with consequent impairment of host defenses, especially
related to infectious agents. (Right) Addition of neutralizing antibodies (Abs) to PD-1 or PD-L1 in
vitro or in vivo reverses the suppressive state, causing restoration of innate immune and
inflammatory responses of phagocytes in sepsis.
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would reverse many decades of failed




Obviously, the number of humans
assessed was only 17, and the reference
nonseptic group was 9. Expanded clinical
studies will also subsequently be needed
to address the following questions:
1. What are the mechanisms behind
the ability of antibodies against PD-1
and/or PD-L1 to reverse in vitro the
defective innate immune responses
of blood leukocytes from septic mice
and human patients?
2. What is the duration of the in vivo
reversal in leukocyte defects in
septic patients?
3. Is there homogeneity in terms of
outcomes of septic patients treated
with the antibodies to checkpoint
inhibitors, or are the outcomes vari-
able? If the latter is the case, what
are the reasons?
4. Do companion studies in septic mice
using the antibodies to PD-1 and
PD-L1 reverse the ability of leukocytes
to respond in vitro to various agonists
(LPS, PMA, C5a, histones)?
5. Does use of the neutralizing anti-
bodies to checkpoint molecules
reverse the harmful effects of sepsis
and/or improve survival in humans
and/or interfere with development
of long-term problems?
6. Does the intervention with anti-
bodies to checkpoint proteins also
attenuate the chain of events de-
veloping after sterile sepsis
(hemorrhagic shock, etc.)?
7. Does intervention with antibodies in
septic mice affect the development
of immunosuppression?
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